Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

9 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-31

Study Completion Date

2020-02-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dual-energy CT (DECT) provides information on the blood volume in tumors and lymph nodes. As tumors respond to treatment, preliminary data suggests that the blood volumes changes as well. Investigators are therefore using DECT to test whether it can be used on radiation treatment to rapidly assess response to treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Functional Lung Imaging With DECT and 4DCT

NCT04702607

Non Small Cell Lung Cancer

COMPLETED

PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy

NCT02035683

Non-small Cell Lung Cancer Metastatic Non-small Cell Lung Cancer Stage IIIB

UNKNOWN NA

Chest X-Ray or Chest CT Scan in Patients at High Risk of Developing Lung Cancer

NCT00006087

Lung Cancer

UNKNOWN NA

Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT Parameter

NCT06441357

Adenocarcinoma of Lung

RECRUITING

Lung Screening Study

NCT00006382

Lung Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-small Cell Lung Cancer Stage III

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged greater than 18 years with a diagnosis of stage III non-small cell lung cancer.
* Planned treatment with either definitive chemoradiotherapy or preoperative chemoradiotherapy followed by surgical resection.
* PET-CT study within 4 weeks of next available DECT study.
* Patients must have measurable primary and nodal disease, defined by at least one lesion (primary and lymph node) greater than 1 cm.
* Kidney function sufficient to tolerate iodine-based CT contrast.
* No allergy to iodine-based contrast.
* Ability to understand and the willingness to sign informed consent.

Exclusion Criteria

* Participants with a prior history of thoracic radiotherapy.
* Participants may not be receiving any other study agents.
* Inability to tolerate CT contrast
* Pregnant women are excluded from this study because radiotherapy has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with radiotherapy, breastfeeding should be discontinued if the mother is treated with radiotherapy. These potential risks may also apply to other agents used in this study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No